Marinus Pharmaceuticals Inc (MRNS) Stock
MRNS is no longer traded. Marinus Pharmaceuticals was delisted from the Nasdaq in February 2025.
Prices on this page are historical; the last trade was February 10, 2025 at $0.55.
Marinus Pharmaceuticals stock price history
MRNS final trading statistics
- Final close
- $0.55
- Final trading day
- Feb 10, 2025
- Market cap at delisting
- $30.37M
- Shares outstanding
- 55.22M
- Final 52-week range
- $0.22 – $10.50
- Avg. volume (final 3 mo.)
- 1,794,805
- All-time high (split-adj.)
- $77.52 · Aug 2015
- All-time low (split-adj.)
- $0.23 · Dec 2024
- Return since IPO
- -98.3%
- Beta
- 1.26
- Book value / share
- $0.31
- Price / book
- 1.79
Marinus Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $30.99M | -$141.4M | -$2.63 |
| FY2022 | $25.48M | -$19.8M | -$3.28 |
| FY2021 | $15.35M | -$101.7M | -$2.69 |
| FY2020 | $1.72M | -$66.6M | -$2.58 |
| FY2019 | $0.00 | -$53.8M | -$3.96 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Marinus Pharmaceuticals stock FAQ
What happened to Marinus Pharmaceuticals stock?
Marinus Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $0.55 on February 10, 2025.
Is MRNS stock still trading?
No. MRNS was delisted from the Nasdaq in February 2025 and no longer trades on a U.S. exchange.
What was the last price of MRNS stock?
MRNS closed at $0.55 on its final trading day, February 10, 2025, for a market value of about $30.37M.
What were Marinus Pharmaceuticals's revenue and earnings in its last full fiscal year?
Marinus Pharmaceuticals reported revenue of $30.99M and net income of -$141.4M in fiscal 2023, its last full year as a public company.
When did Marinus Pharmaceuticals go public?
Marinus Pharmaceuticals Inc stock began trading on July 31, 2014.